Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma.

Steins A, Klaassen R, Jacobs I, Schabel MC, van Lier MGJTB, Ebbing EA, Hectors SJ, Tas SW, Maracle CX, Punt CJA, Siebes M, Bergman JJGHM, Medema JP, Wilmink JW, Mathot RAA, Strijkers GJ, Bijlsma MF, van Laarhoven HWM.

Mol Oncol. 2019 Nov 16. doi: 10.1002/1878-0261.12599. [Epub ahead of print]

2.

Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy.

Jezerskyte E, Saadeh LM, Hagens ERC, Sprangers MAG, Noteboom L, van Laarhoven HWM, Eshuis WJ, van Berge Henegouwen MI, Gisbertz SS.

World J Surg. 2019 Nov 15. doi: 10.1007/s00268-019-05281-8. [Epub ahead of print]

PMID:
31732762
3.

Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma.

Anderegg MCJ, Ruurda JP, Gisbertz SS, Blom RLGM, Sosef MN, Wijnhoven BPL, Hulshof MCCM, Bergman JJGHM, van Laarhoven HWM, van Berge Henegouwen MI.

Eur J Surg Oncol. 2019 Oct 21. pii: S0748-7983(19)30903-5. doi: 10.1016/j.ejso.2019.10.023. [Epub ahead of print]

PMID:
31706717
4.

Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study.

Hagens ERC, Künzli HT, van Rijswijk AS, Meijer SL, Mijnals RCD, Weusten BLAM, Geijsen ED, van Laarhoven HWM, van Berge Henegouwen MI, Gisbertz SS.

Surg Endosc. 2019 Oct 17. doi: 10.1007/s00464-019-07205-y. [Epub ahead of print]

PMID:
31624944
5.

Tailored Web-Based Information for Younger and Older Patients with Cancer: Randomized Controlled Trial of a Preparatory Educational Intervention on Patient Outcomes.

Nguyen MH, Smets EM, Bol N, Loos EF, van Laarhoven HW, Geijsen D, van Berge Henegouwen MI, Tytgat KM, van Weert JC.

J Med Internet Res. 2019 Oct 1;21(10):e14407. doi: 10.2196/14407.

6.

ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.

Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Östman A, Sier CFM, Prakash J.

Sci Adv. 2019 Sep 4;5(9):eaax2770. doi: 10.1126/sciadv.aax2770. eCollection 2019 Sep.

7.

Influence of response shift and disposition on patient-reported outcomes may lead to suboptimal medical decisions: a medical ethics perspective.

Hartog ID, Willems DL, van den Hout WB, Scherer-Rath M, Oreel TH, Henriques JPS, Nieuwkerk PT, van Laarhoven HWM, Sprangers MAG.

BMC Med Ethics. 2019 Sep 11;20(1):61. doi: 10.1186/s12910-019-0397-3.

8.

The Use of (Network) Meta-Analysis in Clinical Oncology.

Ter Veer E, van Oijen MGH, van Laarhoven HWM.

Front Oncol. 2019 Aug 27;9:822. doi: 10.3389/fonc.2019.00822. eCollection 2019.

9.

Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center.

Roos E, Strijker M, Franken LC, Busch OR, van Hooft JE, Klümpen HJ, van Laarhoven HW, Wilmink JW, Verheij J, van Gulik TM, Besselink MG.

HPB (Oxford). 2019 Sep 4. pii: S1365-182X(19)30627-6. doi: 10.1016/j.hpb.2019.07.011. [Epub ahead of print]

PMID:
31494056
10.

From presentation to paper: Gender disparities in oncological research.

Dijksterhuis WPM, Stroes CI, Tan WL, Ithimakin S, Calles A, van Oijen MGH, Verhoeven RHA, Barriuso J, Oosting SF, Ivankovic DK, Furness AJS, Bozovic-Spasojevic I, Gomez-Roca C, van Laarhoven HWM.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32660. [Epub ahead of print]

PMID:
31472016
11.

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Pijl H, Charehbili A, van de Ven S, Smit VTHBM, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJC, Kessels LW, Dercksen MW, Pepels MJAE, van Laarhoven HWM, Vriens BEPJ, Putter H, Fiocco M, Liefers GJ, van der Hoeven JJM, Nortier JWR, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2019 Aug 28;21(1):97. doi: 10.1186/s13058-019-1180-6.

12.

The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis.

Mackay TM, Smits FJ, Roos D, Bonsing BA, Bosscha K, Busch OR, Creemers GJ, van Dam RM, van Eijck CHJ, Gerhards MF, de Groot JWB, Groot Koerkamp B, Haj Mohammad N, van der Harst E, de Hingh IHJT, Homs MYV, Kazemier G, Liem MSL, de Meijer VE, Molenaar IQ, Nieuwenhuijs VB, van Santvoort HC, van der Schelling GP, Stommel MWJ, Ten Tije AJ, de Vos-Geelen J, Wit F, Wilmink JW, van Laarhoven HWM, Besselink MG; Dutch Pancreatic Cancer Group.

HPB (Oxford). 2019 Aug 19. pii: S1365-182X(19)30610-0. doi: 10.1016/j.hpb.2019.06.019. [Epub ahead of print]

PMID:
31439478
13.

COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis.

van den Ende T, Abe Nijenhuis FA, van den Boorn HG, Ter Veer E, Hulshof MCCM, Gisbertz SS, van Oijen MGH, van Laarhoven HWM.

Front Oncol. 2019 Jul 25;9:684. doi: 10.3389/fonc.2019.00684. eCollection 2019.

14.

Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.

Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM.

Int J Cancer. 2019 Jul 24. doi: 10.1002/ijc.32580. [Epub ahead of print]

PMID:
31340065
15.

Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.

Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, Busch OR, van Delden OM, Halfwerk H, van Hooft JE, van Lienden KP, Marchegiani G, Meijer SL, van Noesel CJ, Reinten RJ, Roos E, Schokker S, Verheij J, van de Vijver MJ, Waasdorp C, Wilmink JW, Ylstra B, Besselink MG, Bijlsma MF, Dijk F, van Laarhoven HW.

Int J Cancer. 2019 Jul 24. doi: 10.1002/ijc.32586. [Epub ahead of print]

PMID:
31340061
16.

Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage I-IIIB compared with changes over a similar timeframe in women without cancer.

van den Berg MMGA, Kok DE, Visser M, de Vries JHM, de Kruif JTCM, de Vries Y, Posthuma L, Sommeijer DW, Timmer-Bonte A, Los M, van Laarhoven HWM, Kampman E, Winkels RM.

Support Care Cancer. 2019 Jul 9. doi: 10.1007/s00520-019-04951-6. [Epub ahead of print]

PMID:
31290019
17.

Living with advanced cancer: Rich Pictures as a means for health care providers to explore the experiences of advanced cancer patients.

Bood ZM, Scherer-Rath M, Sprangers MAG, Timmermans L, van Wolde E, Cristancho SM, Heyning F, Russel S, van Laarhoven HWM, Helmich E.

Cancer Med. 2019 Sep;8(11):4957-4966. doi: 10.1002/cam4.2342. Epub 2019 Jul 6.

18.

Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study.

Hagens ERC, van Berge Henegouwen MI, van Sandick JW, Cuesta MA, van der Peet DL, Heisterkamp J, Nieuwenhuijzen GAP, Rosman C, Scheepers JJG, Sosef MN, van Hillegersberg R, Lagarde SM, Nilsson M, Räsänen J, Nafteux P, Pattyn P, Hölscher AH, Schröder W, Schneider PM, Mariette C, Castoro C, Bonavina L, Rosati R, de Manzoni G, Mattioli S, Garcia JR, Pera M, Griffin M, Wilkerson P, Chaudry MA, Sgromo B, Tucker O, Cheong E, Moorthy K, Walsh TN, Reynolds J, Tachimori Y, Inoue H, Matsubara H, Kosugi SI, Chen H, Law SYK, Pramesh CS, Puntambekar SP, Murthy S, Linden P, Hofstetter WL, Kuppusamy MK, Shen KR, Darling GE, Sabino FD, Grimminger PP, Meijer SL, Bergman JJGHM, Hulshof MCCM, van Laarhoven HWM, Mearadji B, Bennink RJ, Annema JT, Dijkgraaf MGW, Gisbertz SS.

BMC Cancer. 2019 Jul 4;19(1):662. doi: 10.1186/s12885-019-5761-7.

19.

Vlogging at the end of life.

Sánchez-Querubín N, van Laarhoven HWM.

Lancet Oncol. 2019 Jul;20(7):911-912. doi: 10.1016/S1470-2045(19)30330-4. No abstract available.

PMID:
31267960
20.

Quality of life during palliative systemic therapy for oesophagogastric cancer: systematic review and meta-analysis.

van Kleef JJ, Ter Veer E, van den Boorn HG, Schokker S, Ngai LL, Prins MJ, Mohammad NH, van de Poll-Franse LV, Zwinderman AH, van Oijen MGH, Sprangers MAG, van Laarhoven HWM.

J Natl Cancer Inst. 2019 Jun 28. pii: djz133. doi: 10.1093/jnci/djz133. [Epub ahead of print]

PMID:
31251346
21.

Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin.

Takeuchi M, Ajani JA, Fang X, Pfeiffer P, Takeuchi M, van Laarhoven HWM.

Cancers (Basel). 2019 Jun 21;11(6). pii: E871. doi: 10.3390/cancers11060871.

22.

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).

Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM.

Cancers (Basel). 2019 Jun 14;11(6). pii: E827. doi: 10.3390/cancers11060827.

23.

Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment.

Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E.

Ther Adv Med Oncol. 2019 May 10;11:1758835919841233. doi: 10.1177/1758835919841233. eCollection 2019.

24.

Postoperative surveillance of pancreatic cancer patients.

Daamen LA, Groot VP, Intven MPW, Besselink MG, Busch OR, Koerkamp BG, Mohammad NH, Hermans JJ, van Laarhoven HWM, Nuyttens JJ, Wilmink JW, van Santvoort HC, Molenaar IQ, Stommel MWJ; Dutch Pancreatic Cancer Group.

Eur J Surg Oncol. 2019 Oct;45(10):1770-1777. doi: 10.1016/j.ejso.2019.05.031. Epub 2019 Jun 1. Review.

PMID:
31204168
25.

Contradiction between amide-CEST signal and pH in breast cancer explained with metabolic MRI.

Krikken E, van der Kemp WJM, Khlebnikov V, van Dalen T, Los M, van Laarhoven HWM, Luijten PR, van den Bosch MAAJ, Klomp DWJ, Wijnen JP.

NMR Biomed. 2019 Aug;32(8):e4110. doi: 10.1002/nbm.4110. Epub 2019 May 28.

26.

Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.

Willemsen AECAB, Krausz S, Ligtenberg MJL, Grünberg K, Groen HJM, Voest EE, Cuppen EPJG, van Laarhoven HWM, van Herpen CML.

Br J Cancer. 2019 Jul;121(1):34-36. doi: 10.1038/s41416-019-0489-3. Epub 2019 May 27.

PMID:
31130724
27.

Spiritual care by nurses in curative oncology: a mixed-method study on patients' perspectives and experiences.

Ebenau A, Groot M, Visser A, van Laarhoven HWM, van Leeuwen R, Garssen B.

Scand J Caring Sci. 2019 May 16. doi: 10.1111/scs.12710. [Epub ahead of print]

PMID:
31095760
28.

A novel amplitude binning strategy to handle irregular breathing during 4DMRI acquisition: improved imaging for radiotherapy purposes.

van Kesteren Z, van der Horst A, Gurney-Champion OJ, Bones I, Tekelenburg D, Alderliesten T, van Tienhoven G, Klaassen R, van Laarhoven HWM, Bel A.

Radiat Oncol. 2019 May 14;14(1):80. doi: 10.1186/s13014-019-1279-z.

29.

Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis.

van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM.

Cancers (Basel). 2019 Apr 26;11(5). pii: E588. doi: 10.3390/cancers11050588. Review.

30.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

31.

Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.

Steins A, Ebbing EA, Creemers A, van der Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, van Delden OM, Krishnadath KK, Hulshof MCCM, Bennink RJ, Punt CJA, Medema JP, Bijlsma MF, van Laarhoven HWM.

Int J Cancer. 2019 Nov 15;145(10):2792-2803. doi: 10.1002/ijc.32364. Epub 2019 May 7.

32.

TOXview: a novel graphical presentation of cancer treatment toxicity profiles.

Ngai LL, Ter Veer E, van den Boorn HG, van Herk EH, van Kleef JJ, van Oijen MGH, van Laarhoven HWM.

Acta Oncol. 2019 Aug;58(8):1138-1148. doi: 10.1080/0284186X.2019.1601256. Epub 2019 Apr 24.

PMID:
31017020
33.

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis.

van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Apr 12;11(4). pii: E530. doi: 10.3390/cancers11040530.

34.

Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.

van Veldhuisen E, Walma MS, van Rijssen LB, Busch OR, Bruijnen RCG, van Delden OM, Mohammad NH, de Hingh IH, Yo LS, van Laarhoven HW, van Leeuwen MS, Nio CY, van Santvoort HC, de Vries J, Wessels FJ, Wilmink JW, Molenaar IQ, Besselink MG, van Lienden KP; Dutch Pancreatic Cancer Group.

HPB (Oxford). 2019 Oct;21(10):1385-1392. doi: 10.1016/j.hpb.2019.02.017. Epub 2019 Apr 19.

35.

Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival.

van Putten M, Lemmens VEPP, van Laarhoven HWM, Pruijt HFM, Nieuwenhuijzen GAP, Verhoeven RHA.

Eur J Surg Oncol. 2019 Oct;45(10):1926-1933. doi: 10.1016/j.ejso.2019.03.040. Epub 2019 Apr 6.

PMID:
30982656
36.

Principal component analysis fosr fast and model-free denoising of multi b-value diffusion-weighted MR images.

Gurney-Champion OJ, Collins DJ, Wetscherek A, Rata M, Klaassen R, van Laarhoven HWM, Harrington KJ, Oelfke U, Orton MR.

Phys Med Biol. 2019 May 17;64(10):105015. doi: 10.1088/1361-6560/ab1786.

PMID:
30965296
37.

Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.

Mokadem I, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP, van Laarhoven HWM, Verhoeven RHA.

Gastric Cancer. 2019 Nov;22(6):1263-1273. doi: 10.1007/s10120-019-00956-6. Epub 2019 Apr 4.

38.

Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T.

Krikken E, van der Kemp WJM, van Diest PJ, van Dalen T, van Laarhoven HWM, Luijten PR, Klomp DWJ, Wijnen JP.

NMR Biomed. 2019 Jun;32(6):e4086. doi: 10.1002/nbm.4086. Epub 2019 Mar 29.

39.

Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.

van den Ende T, Menting SP, Ambarus CA, van Oijen MGH, van Laarhoven HWM.

Oncologist. 2019 Apr;24(4):e149-e153. doi: 10.1634/theoncologist.2018-0674. Epub 2019 Mar 22.

PMID:
30902915
40.

Cardiac molecular pathways influenced by doxorubicin treatment in mice.

Bulten BF, Sollini M, Boni R, Massri K, de Geus-Oei LF, van Laarhoven HWM, Slart RHJA, Erba PA.

Sci Rep. 2019 Feb 21;9(1):2514. doi: 10.1038/s41598-019-38986-w.

41.

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.

van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187.

42.

Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer.

Strijker M, Chen JW, Mungroop TH, Jamieson NB, van Eijck CH, Steyerberg EW, Wilmink JW, Groot Koerkamp B, van Laarhoven HW, Besselink MG.

Br J Surg. 2019 Mar;106(4):342-354. doi: 10.1002/bjs.11111. Epub 2019 Feb 13.

PMID:
30758855
43.

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.

Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22.

44.

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.

Dijksterhuis WPM, Pruijt MJ, van der Woude SO, Klaassen R, Kurk SA, van Oijen MGH, van Laarhoven HWM.

J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):199-206. doi: 10.1002/jcsm.12371. Epub 2019 Jan 21.

45.

Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy.

Kok DE, van den Berg MMGA, Posthuma L, van 't Erve I, van Duijnhoven FJB, de Roos WK, Grosfeld S, Los M, Sommeijer DW, van Laarhoven HWM, Winkels RM, Kampman E.

Nutr Cancer. 2019;71(5):756-766. doi: 10.1080/01635581.2018.1559938. Epub 2019 Jan 19.

PMID:
30661404
46.

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis.

van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Jan 11;11(1). pii: E80. doi: 10.3390/cancers11010080.

47.

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study.

Jelvehgaran P, Alderliesten T, Georgiou G, Meijer SL, Bloemen PR, Kodach LL, van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM, Rasch CRN, van Leeuwen TG, de Boer JF, de Bruin M, van Herk M.

Biomed Opt Express. 2018 Aug 14;9(9):4196-4216. doi: 10.1364/BOE.9.004196. eCollection 2018 Sep 1.

48.

A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.

de Kruif JTCM, Visser M, van den Berg MMGA, Derks MJM, de Boer MR, van Laarhoven HWM, de Vries JHM, de Vries YC, Kampman E, Winkels RW, Westerman MJ.

BMC Cancer. 2019 Jan 5;19(1):7. doi: 10.1186/s12885-018-5207-7.

49.

Promoting shared decision making in advanced cancer: Development and piloting of a patient communication aid.

Henselmans I, Brugel SD, de Haes HCJM, Wolvetang KJA, de Vries LM, Pieterse AH, Baas-Thijssen MCM, de Vos FYF, van Laarhoven HWM, Smets EMA.

Patient Educ Couns. 2019 May;102(5):916-923. doi: 10.1016/j.pec.2018.12.018. Epub 2018 Dec 14.

PMID:
30591283
50.

The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer.

Jeene PM, van Laarhoven HWM, Hulshof MCCM.

Best Pract Res Clin Gastroenterol. 2018 Oct - Dec;36-37:53-59. doi: 10.1016/j.bpg.2018.11.011. Epub 2018 Nov 21. Review.

PMID:
30551857

Supplemental Content

Loading ...
Support Center